Document Type
Article
Publication Date
1-2003
Abstract
Patenting genes encoding therapeutic proteins was relatively uncontroversial in the early days of biotechnology. Controversy arose in the era of high-throughput DNA sequencing, when gene patents started to look less like patents on drugs and more like patents on scientific information. Evolving scientific and business strategies for exploiting genomic information raised concerns that patents might slow subsequent research. The trend towards stricter enforcement of the utility and disclosure requirements by the patent offices should help clarify the current confusion.
Recommended Citation
Eisenberg, Rebecca S. "Patenting Genome Research Tools and the Law." Comptes rendus Biologies 326, no. 10-11 (2003): 1115-1120.
Included in
Biotechnology Commons, Intellectual Property Law Commons, Science and Technology Law Commons
Comments
Reproduced from Eisenberg, Rebecca S. Patenting Genome Research Tools and the Law. Comptes rendus Biologies 2003;326(10-11):1115-1120. DOI: https://doi.org/10.1016/j.crvi.2003.10.001
Copyright © 2003 published by Elsevier Masson SAS. All rights reserved.